# Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy Adults

> **NCT04940845** · PHASE1 · UNKNOWN · sponsor: **Shanghai Hansoh Biomedical Co., Ltd** · enrollment: 174 (estimated)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** HS-20090-2
- **DRUG:** Prolia

## Key facts

- **NCT ID:** NCT04940845
- **Lead sponsor:** Shanghai Hansoh Biomedical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-26
- **Primary completion:** 2022-06
- **Final completion:** 2022-06
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2021-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04940845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04940845, "Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy Adults". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04940845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*